Allurion to Participate in Upcoming Investor Conferences
Allurion Technologies (NYSE: ALUR), a company focused on ending obesity, has announced its participation in two major upcoming investor conferences. Dr. Shantanu Gaur, Founder and CEO, will present at the 45th Annual TD Cowen Healthcare Conference in Boston on March 3, 2025, at 9:10 a.m. ET, where he will also conduct one-on-one investor meetings.
Additionally, Dr. Gaur will host individual investor meetings at the 37th Annual Roth Conference in Dana Point, California, from March 16-18, 2025. Investors can access the presentation webcast through the Events & Presentations section of Allurion's investor relations website.
Allurion Technologies (NYSE: ALUR), un'azienda focalizzata sulla lotta contro l'obesità, ha annunciato la sua partecipazione a due importanti conferenze per investitori in arrivo. Il Dott. Shantanu Gaur, Fondatore e CEO, presenterà alla 45ª Conferenza Sanitaria Annuale TD Cowen a Boston il 3 marzo 2025, alle 9:10 ET, dove condurrà anche incontri individuali con gli investitori.
Inoltre, il Dott. Gaur ospiterà incontri individuali con gli investitori alla 37ª Conferenza Annuale Roth a Dana Point, California, dal 16 al 18 marzo 2025. Gli investitori possono accedere alla trasmissione in diretta della presentazione attraverso la sezione Eventi e Presentazioni del sito web delle relazioni con gli investitori di Allurion.
Allurion Technologies (NYSE: ALUR), una empresa centrada en acabar con la obesidad, ha anunciado su participación en dos importantes conferencias para inversores que se avecinan. El Dr. Shantanu Gaur, Fundador y CEO, presentará en la 45ª Conferencia Anual de Salud TD Cowen en Boston el 3 de marzo de 2025, a las 9:10 a.m. ET, donde también llevará a cabo reuniones individuales con inversores.
Además, el Dr. Gaur será el anfitrión de reuniones individuales con inversores en la 37ª Conferencia Anual Roth en Dana Point, California, del 16 al 18 de marzo de 2025. Los inversores pueden acceder a la transmisión en vivo de la presentación a través de la sección de Eventos y Presentaciones del sitio web de relaciones con inversores de Allurion.
알루리온 테크놀로지스 (NYSE: ALUR)는 비만 퇴치를 목표로 하는 회사로, 앞으로 열릴 두 개의 주요 투자자 회의에 참여할 것이라고 발표했습니다. 샨타누 가우르 박사, 창립자이자 CEO는 2025년 3월 3일 오전 9시 10분 ET에 보스턴에서 열리는 제45회 TD 코웬 헬스케어 컨퍼런스에서 발표할 예정이며, 이 자리에서 개별 투자자 회의도 진행할 것입니다.
또한, 가우르 박사는 2025년 3월 16일부터 18일까지 캘리포니아 다나 포인트에서 열리는 제37회 로스 컨퍼런스에서 개별 투자자 회의를 주최할 것입니다. 투자자들은 알루리온의 투자자 관계 웹사이트의 이벤트 및 발표 섹션을 통해 발표 웹캐스트에 접근할 수 있습니다.
Allurion Technologies (NYSE: ALUR), une entreprise axée sur la lutte contre l'obésité, a annoncé sa participation à deux grandes conférences pour investisseurs à venir. Dr. Shantanu Gaur, Fondateur et PDG, présentera lors de la 45e Conférence Annuelle TD Cowen sur la Santé à Boston le 3 mars 2025 à 9h10 ET, où il tiendra également des réunions individuelles avec les investisseurs.
De plus, le Dr. Gaur animera des réunions individuelles avec les investisseurs lors de la 37e Conférence Annuelle Roth à Dana Point, Californie, du 16 au 18 mars 2025. Les investisseurs peuvent accéder à la diffusion en direct de la présentation via la section Événements et Présentations du site Web des relations avec les investisseurs d'Allurion.
Allurion Technologies (NYSE: ALUR), ein Unternehmen, das sich der Bekämpfung von Fettleibigkeit widmet, hat seine Teilnahme an zwei bevorstehenden wichtigen Investorenkonferenzen angekündigt. Dr. Shantanu Gaur, Gründer und CEO, wird am 3. März 2025 um 9:10 Uhr ET auf der 45. jährlichen TD Cowen Gesundheitskonferenz in Boston präsentieren, wo er auch Einzelgespräche mit Investoren führen wird.
Darüber hinaus wird Dr. Gaur individuelle Investorenmeetings auf der 37. jährlichen Roth-Konferenz in Dana Point, Kalifornien, vom 16. bis 18. März 2025 abhalten. Investoren können über den Bereich Veranstaltungen und Präsentationen auf der Investor Relations-Website von Allurion auf den Präsentations-Webcast zugreifen.
- None.
- None.
Dr. Shantanu Gaur, Founder and Chief Executive Officer, will present at 9:10 a.m. ET and host one-on-one investor meetings throughout the day on March 3, 2025, at the 45th Annual TD Cowen Healthcare Conference in
A webcast of the presentation will be available in the Events & Presentations section of Allurion’s investor relations website.
About Allurion
Allurion is dedicated to ending obesity. The Allurion Program is a weight-loss platform that combines the Allurion Gastric Balloon, the world’s first and only swallowable, procedure-lessTM gastric balloon for weight loss, the Allurion Virtual Care Suite, including the Allurion Mobile App for consumers and Allurion Insights for healthcare providers featuring the Iris AI Platform, and the Allurion Connected Scale. The Allurion Virtual Care Suite is also available to providers separately from the Allurion Program to help customize, monitor, and manage weight-loss therapy for patients regardless of their treatment plan. The Allurion Gastric Balloon is an investigational device in
For more information about Allurion and the Allurion Virtual Care Suite, please visit www.allurion.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250225247479/en/
Global Media and Investor Inquiries
Hannah Lindberg
hlindberg@allurion.com
Source: Allurion Technologies, Inc.
FAQ
When and where will Allurion Technologies (ALUR) present at the TD Cowen Healthcare Conference?
What investor conferences will Allurion (ALUR) attend in March 2025?
How can investors access Allurion's (ALUR) conference presentation?
What dates will Allurion (ALUR) attend the Roth Conference in California?
